Clinical Trial Update: Open-Label Study to Evaluate Safety of A Single Dose of SYM-1219 [Phase 3]

View source ↗

Summary

Open-label Phase 3 trial evaluating a single-dose SYM-1219 for safety in bacterial vaginosis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacterial Vaginosis

Drugs mentioned

• SYM-1219

Snippet

Sponsor: Symbiomix Therapeutics | Conditions: Bacterial Vaginosis | Phase 3 | Status: COMPLETED | Results posted: 2021-04-13